Island Pharmaceuticals Advances Galidesivir Toward FDA Alignment
Island Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted a Type C meeting request under its Investigational New Drug (IND) application for Galidesivir, advancing efforts to fast-track approval for treating the Marburg virus under the Animal Rule. The FDA will provide written feedback following Island’s submission of historical data. This milestone marks a key step toward the company’s goal of supplying antiviral solutions for government stockpiles and high-priority public health threats. 
Island Pharmaceuticals Advances Galidesivir Toward FDA Alignment